Fiscal 2020 First Quarter Highlights
- Net sales of $66.0 million, an increase of 3.3% year over
year
- Gross margin increased 170 basis points year over year to
57.9%
- GAAP loss per share of $0.03; adjusted earnings per share of
$0.08
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease, and oncology, today announced
financial results for the first quarter of fiscal year 2020, which
ended August 31, 2019.
“Our top-line and gross-margin performance in the quarter was in
line with our expectations,” commented Jim Clemmer, President and
Chief Executive Officer of AngioDynamics, Inc. “We continue to
build momentum and remain focused on driving growth by creating a
suite of disruptive and differentiated technology. The divestiture
of the NAMIC Fluid Management business allowed us to begin the year
with a strong balance sheet, enabling strategic acquisitions like
Eximo Medical, Ltd., which we announced this morning. Additionally,
we continue to make steady progress with site initiation in our
NanoKnife DIRECT study for pancreatic cancer.”
First Quarter 2020 Financial Results
Net sales for the first quarter of fiscal 2020 were $66.0
million, an increase of 3.3%, compared to $63.9 million a year ago
and representing a decline of 1.0% organically. Excluding the
impact of Asclera, sales of which were discontinued during fiscal
year 2019, net sales grew 5.6% year over year and grew 1.3%
organically. Foreign currency translation did not have a
significant impact on the Company’s sales in the quarter.
- Oncology net sales were $14.0 million, an increase of 20.9%
from $11.6 million a year ago, led by sales of the Company’s
BioSentry Tract Sealant System, the Alatus and IsoLoc balloon
products, NanoKnife, and Solero.
- Vascular Interventions and Therapies (“VIT”) net sales were
$28.9 million, an increase of 1.1%, compared to $28.6 million a
year ago. Excluding last year’s Asclera Sales of $1.4 million in
the first quarter, VIT grew 6.4%, as strong growth in sales of the
Company’s AngioVac and Thrombolytic product line offerings was
partially offset by a decline in the overall Core VIT
business.
- Vascular Access net sales were $23.2 million, a decrease of
2.7% from $23.8 million a year ago, as lower sales of Ports and
PICCs negatively offset growth in the Midlines and Dialysis
businesses.
U.S. net sales in the first quarter of fiscal 2020 were $52.9
million, an increase of 2.8% from $51.5 million a year ago, and
International net sales were $13.1 million, an increase of 5.3%
from $12.4 million a year ago.
Gross margin for the first quarter of fiscal 2020 was 57.9%, an
increase of 170 basis points compared to the first quarter of
fiscal 2019, driven primarily by productivity and supply chain
improvements as well as positive product mix.
The Company recorded a net loss from continuing operations of
$1.3 million, or a loss of $0.03 per share, in the first quarter of
fiscal 2020. This compares to a net loss from continuing operations
of approximately $5.7 million, or a loss of $0.15 per share, a year
ago.
Excluding the items shown in the non-GAAP reconciliation table
below, adjusted net income for the first quarter of fiscal 2020 was
$3.2 million, or $0.08 per share, compared to adjusted net income
of $0.7 million, or $0.02 per share, in the first quarter of fiscal
2019.
Adjusted EBITDAS in the first quarter of fiscal 2020, excluding
the items shown in the reconciliation table below, was $7.3
million, compared to $5.4 million in the first quarter of fiscal
2019.
In the first quarter of fiscal 2020, the Company used $6.5
million in operating cash flow and had capital expenditures of $1.4
million. As of August 31, 2019, the Company had $83.6 million in
cash and cash equivalents and no debt outstanding.
Fiscal Year 2020 Financial Guidance
The Company continues to expect fiscal year 2020 net sales to be
in the range of $280 to $286 million and gross margin to be in the
range of 58% to 59%, inclusive of the Eximo acquisition.
Separately, the Company is updating its expectations for
full-year adjusted earnings per share to account for investments
related to the full-market launch of the products acquired from
Eximo, anticipated in the second half of fiscal year 2020, and now
expects adjusted earnings per share in the range of $0.10 to
$0.15.
Conference Call
The Company’s management will host a conference call today at
8:00 a.m. ET to discuss its fiscal 2020 first quarter results.
To participate in the conference call, dial 1-877-407-0784
(domestic) or +1-201-689-8560 (international) and refer to the
passcode 13694372.
This conference call will also be webcast and can be accessed
from the “Investors” section of the AngioDynamics website at
www.angiodynamics.com. The webcast replay of the call will be
available at the same site approximately one hour after the end of
the call.
A recording of the call will also be available from 11:00 a.m.
ET on Thursday, October 3, 2019, until 11:59 p.m. ET on Thursday,
October 10, 2019. To hear this recording, dial 1-844-512-2921
(domestic) or +1-412-317-6671 (international) and enter the
passcode 13694372.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals
and believes that non-GAAP measures may assist investors in
analyzing the underlying trends in AngioDynamics' business over
time. Investors should consider these non-GAAP measures in addition
to, not as a substitute for or as superior to, financial reporting
measures prepared in accordance with GAAP. In this news release,
AngioDynamics has reported adjusted EBITDAS, adjusted net income,
adjusted earnings per share, free cash flow and net sales on an
organic basis, excluding acquired assets and Asclera. Management
uses these measures in its internal analysis and review of
operational performance. Management believes that these measures
provide investors with useful information in comparing
AngioDynamics' performance over different periods. By using these
non-GAAP measures, management believes that investors get a better
picture of the performance of AngioDynamics' underlying business.
Management encourages investors to review AngioDynamics' financial
results prepared in accordance with GAAP to understand
AngioDynamics' performance taking into account all relevant
factors, including those that may only occur from time to time but
have a material impact on AngioDynamics' financial results. Please
see the tables that follow for a reconciliation of non-GAAP
measures to measures prepared in accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare
providers for vascular access, peripheral vascular disease, and
oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems, vascular access products,
angiographic products and accessories, drainage products,
thrombolytic products and venous products. For more information,
visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements regarding AngioDynamics' expected future financial
position, results of operations, cash flows, business strategy,
budgets, projected costs, capital expenditures, products,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include the words such as "expects," "reaffirms," "intends,"
"anticipates," "plans," "believes," "seeks," "estimates,"
"optimistic," or variations of such words and similar expressions,
are forward-looking statements. These forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties. Investors are cautioned that actual events or
results may differ from AngioDynamics' expectations. Factors that
may affect the actual results achieved by AngioDynamics include,
without limitation, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents
attained by competitors, infringement of AngioDynamics' technology
or assertions that AngioDynamics' technology infringes the
technology of fourth parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially
greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall
economic conditions, the results of on-going litigation, challenges
with respect to fourth-party distributors or joint venture partners
or collaborators, the results of sales efforts, the effects of
product recalls and product liability claims, changes in key
personnel, the ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market
conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from
group purchasing organizations and competition, the ability of
AngioDynamics to integrate acquired businesses, as well as the risk
factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the
year ended May 31, 2019. AngioDynamics does not assume any
obligation to publicly update or revise any forward-looking
statements for any reason.
In the United States, the NanoKnife System has received a 510(k)
clearance by the Food and Drug Administration for use in the
surgical ablation of soft tissue and is similarly approved for
commercialization in Canada, the European Union, and Australia. The
NanoKnife System has not been cleared for the treatment or therapy
of a specific disease or condition.
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
CONSOLIDATED INCOME
STATEMENTS
(in thousands, except per share
data)
Three months ended
August 31,
August 31,
2019
2018
(unaudited)
Net sales
$
66,042
$
63,943
Cost of sales (exclusive of intangible
amortization)
27,825
27,990
Gross profit
38,217
35,953
% of net sales
57.9
%
56.2
%
Operating expenses
Research and development
6,292
7,374
Sales and marketing
19,380
18,405
General and administrative
8,453
8,435
Amortization of intangibles
3,868
3,434
Change in fair value of contingent
consideration
(448
)
12
Acquisition, restructuring and other
items, net
1,500
4,422
Total operating expenses
39,045
42,082
Operating income
(828
)
(6,129
)
Interest expense, net
(465
)
(917
)
Other income (expense), net
(98
)
114
Total other expense, net
(563
)
(803
)
Loss from continuing operations before
income taxes
(1,391
)
(6,932
)
Income tax benefit
(116
)
(1,228
)
Net loss from continuing operations
(1,275
)
(5,704
)
Net Income from discontinued
operations
—
5,235
Net loss
$
(1,275
)
$
(469
)
Loss per share - continuing operations
Basic
$
(0.03
)
$
(0.15
)
Diluted
$
(0.03
)
$
(0.15
)
Income per share - discontinued
operations
Basic
$
—
$
0.14
Diluted
$
—
$
0.14
Loss per share
Basic
$
(0.03
)
$
(0.01
)
Diluted
$
(0.03
)
$
(0.01
)
Weighted average shares outstanding
Basic
37,783
37,323
Diluted
37,783
37,323
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
GAAP TO NON-GAAP
RECONCILIATION
(in thousands, except per share
data)
Reconciliation of Net Loss to non-GAAP
Adjusted Net Income:
Three months ended
August 31,
August 31,
2019
2018
(unaudited)
Net loss from continuing operations
$
(1,275
)
$
(5,704
)
Amortization of intangibles
3,868
3,434
Change in fair value of contingent
consideration
(448
)
12
Acquisition, restructuring and other
items, net (1)
1,500
4,422
Write-off of deferred financing fees
(2)
593
—
Tax effect of non-GAAP items (3)
(1,064
)
(1,443
)
Adjusted net income
$
3,174
$
721
Reconciliation of Diluted Earnings Per
Share to non-GAAP Adjusted Diluted Earnings Per Share:
Three months ended
August 31,
August 31,
2019
2018
(unaudited)
Diluted loss per share
$
(0.03
)
$
(0.15
)
Amortization of intangibles
0.10
0.09
Change in fair value of contingent
consideration
(0.01
)
0.00
Acquisition, restructuring and other
items, net (1)
0.04
0.12
Write-off of deferred financing fees
(2)
0.02
—
Tax effect of non-GAAP items (3)
(0.04
)
(0.04
)
Adjusted diluted earnings per share
$
0.08
$
0.02
Adjusted diluted sharecount
38,158
38,096
(1) Includes costs related to merger and
acquisition activities, restructuring, and unusual items, including
asset impairments and write-offs, certain litigation, and other
items.
(2) Deferred financing fees related to the
old credit agreement were written off during the first quarter of
fiscal year 2020.
(3) Adjustment to reflect the income tax
provision on a non-GAAP basis has been calculated assuming no
valuation allowance on the Company's U.S. deferred tax assets and
an effective tax rate of 23% for August 31, 2019 and 2018.
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
GAAP TO NON-GAAP
RECONCILIATION (Continued)
(in thousands, except per share
data)
Reconciliation of Net Income to EBITDAS
and Adjusted EBITDAS:
Three months ended
August 31,
August 31,
2019
2018
(unaudited)
Net loss from continuing operations
$
(1,275
)
$
(5,704
)
Income tax expense (benefit)
(116
)
(1,228
)
Interest expense, net
465
917
Depreciation and amortization
5,170
4,812
Stock based compensation
1,984
2,143
EBITDAS
$
6,228
$
940
Change in fair value of contingent
consideration
$
(448
)
$
12
Acquisition, restructuring and other
items, net (1)
1,500
4,422
Adjusted EBITDAS
$
7,280
$
5,374
Per diluted share:
EBITDAS
$
0.16
$
0.02
Adjusted EBITDAS
$
0.19
$
0.14
(1) Includes costs related to
merger and acquisition activities, restructuring, and unusual
items, including asset impairments and write-offs, certain
litigation, and other items.
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY
AND BY GEOGRAPHY
(in thousands)
Three months ended
Aug 31, 2019
Aug 31, 2018
% Growth
Currency Impact
Constant Currency Growth
Net Sales by Product Category
Vascular Interventions & Therapies
$
28,913
$
28,598
1.1%
Vascular Access
23,159
23,790
(2.7)%
Oncology
13,970
11,555
20.9%
Total
$
66,042
$
63,943
3.3%
1.0%
3.5%
Net Sales by Geography
United States
$
52,937
$
51,496
2.8%
0.0%
2.8%
International
13,105
12,447
5.3%
1.0%
6.4%
Total
$
66,042
$
63,943
3.3%
1.0%
3.5%
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
CONSOLIDATED BALANCE
SHEETS
(in thousands)
August 31, 2019
May 31, 2019
(unaudited)
(audited)
Assets
Current assets:
Cash and cash equivalents
$
83,649
$
227,641
Total cash and investments
83,649
227,641
Accounts receivable, net
32,540
43,577
Inventories
45,229
40,071
Prepaid expenses and other
4,939
4,003
Total current assets
166,357
315,292
Property, plant and equipment, net
25,334
24,258
Other assets
9,352
3,835
Intangible assets, net
141,655
145,387
Goodwill
347,666
347,666
Total assets
$
690,364
$
836,438
Liabilities and stockholders'
equity
Current liabilities:
Accounts payable
$
16,870
$
22,829
Accrued liabilities
22,693
38,338
Current portion of long-term debt
—
7,500
Current portion of contingent
consideration
878
4,635
Other current liabilities
6,731
—
Total current liabilities
47,172
73,302
Long-term debt, net of current portion
—
124,407
Deferred income taxes
14,367
14,542
Contingent consideration, net of current
portion
10,952
8,851
Other long-term liabilities
3,800
521
Total liabilities
76,291
221,623
Stockholders' equity
614,073
614,815
Total Liabilities and Stockholders'
Equity
$
690,364
$
836,438
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CASH FLOWS
(in thousands)
Three months ended
August 31,
August 31,
2019
2018
(unaudited)
Cash flows from operating
activities:
Net loss from continuing operations
$
(1,275
)
$
(469
)
Adjustments to reconcile net loss to net
cash provided by operating activities:
Depreciation and amortization
5,207
5,599
Stock based compensation
1,984
2,150
Change in fair value of contingent
consideration
(448
)
12
Deferred income taxes
(175
)
(10
)
Change in accounts receivable
allowances
(453
)
(228
)
Fixed and intangible asset impairments and
disposals
99
—
Write-off of other assets
593
—
Other
(8
)
25
Changes in operating assets and
liabilities, net of acquisitions:
Accounts receivable
11,474
(562
)
Inventories
(5,153
)
(761
)
Prepaid expenses and other
(746
)
(1,200
)
Accounts payable, accrued and other
liabilities
(17,633
)
(13,429
)
Net cash used in operating
activities
(6,534
)
(8,873
)
Cash flows from investing
activities:
Additions to property, plant and
equipment
(1,391
)
(682
)
Acquisition of intangibles
(150
)
—
Cash paid in acquisition
—
(37,000
)
Net cash used in investing
activities
(1,541
)
(37,682
)
Cash flows from financing
activities:
Repayment of long-term debt
(132,500
)
(1,250
)
Deferred financing costs on long-term
debt
(741
)
—
Payment of contingent consideration
previously established in purchase accounting
(1,208
)
(2,100
)
Proceeds (outlays) from exercise of stock
options and employee stock purchase plan
(1,300
)
705
Net cash used in financing
activities
(135,749
)
(2,645
)
Effect of exchange rate changes on cash
and cash equivalents
(168
)
(134
)
Decrease in cash and cash
equivalents
(143,992
)
(49,334
)
Cash and cash equivalents at beginning of
period
227,641
74,096
Cash and cash equivalents at end of
period
$
83,649
$
24,762
ANGIODYNAMICS, INC. AND
SUBSIDIARIES
GAAP TO NON-GAAP
RECONCILIATION
(in thousands)
Reconciliation of Free Cash
Flows:
Three months ended
August 31,
August 31,
2019
2018
(unaudited)
Net cash used in operating activities
$
(6,534
)
$
(8,873
)
Additions to property, plant and
equipment
(1,391
)
(682
)
Free Cash Flow
$
(7,925
)
$
(9,555
)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191003005216/en/
Investors:
AngioDynamics, Inc. Michael C. Greiner, Executive Vice President
& CFO (518) 795-1821
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2023 to Apr 2024